FDA Backs New Treatment for Motor Neurone Disease

Phytopharm in Huntingdon, England has been granted orphan drug status by the US FDA for Cogane, an experimental treatment for ALS. According to the article, Cogane has already shown “promising” activity in preclinical in vitro models of ALS. A study funded by the UK based Motor Neurone Disease Association will determine Cogane‚Äôs effects in the genetic ‘gold standard’ in vivo model of ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail